Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | K. Klement et al., J. Cell Biol., Dec 2014; 207: 717 - 733 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | T.-H. Kang et al., Mol. Cell. Biol., Dec 2007; 27: 8533 - 8546 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | J. Arias-del-Val, Cell Calcium, 2019, 77: 68–76, doi.org/10.1016/j.ceca.2018.12.004 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Silvestri et al., Hum. Mol. Genet., Nov 2005; 14: 3477 - 3492 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | Y. P. Abudu et al., J. Cell Biol., 2021, 220(8): e202009092, doi: 10.1083/jcb.202009092 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene EASY | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | M. R. Spinosa et al., J. Neurosci., Feb 2008; 28: 1640 - 1648 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene SI | publication | R. Romano et al., Cell. and Mol. Life Sci., 2021, 78: 351–372, 78:351–372, doi.org/10.1007/s00018-020-03510-1 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | V. De Leo et al., Toxicol. Res., 2017, 6: 947, DOI: 10.1039/c7tx00172 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | N. Mukhamedova et al., J. Lipid Res., Nov 2008; 49: 2312 - 2322 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | plasmid | Metafectene | publication | P. Aridon, Parkinsonism and Related Disorders, 2016, 31:135-138, doi.org/10.1016/j.parkreldis.2016.08.016 | ||||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | T. Sasazuki et al., J. Biol. Chem., Aug 2002; 277: 28853 - 28860 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | H. L. Olsvik et al., J. Biol. Chem., Dec 2015; 290: 29361 - 29374 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | K2 Transfection System | publication | C. D. Zappia et al., Scientific Reports, 2015, 5:17476, DOI: 10.1038/srep17476 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/siRNA) | Metafectene | publication | X. M. M. Weyel, Dissertation, 2018, Goethe- Universität in Frankfurt am Main | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | C. T. Hellwig et al., J. Cell Sci., May 2010; 123: 1401 - 1406 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | C. Dolde et al., Journal of Cell Science, 2018, 131, jcs207316, doi:10.1242/jcs.207316 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | S. Gebremedhin et al., Biophysical J., 2014, 106(2): 625a | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | R. Boudra et al., Cell Cycle, 2016, 15:10,1352-1362; DOI: 10.1080/15384101.2016.1166319 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. G. Theis et al., PNAS, Aug 2004; 101: 11221 - 11226 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | oligonucleotide | DOTAP | publication | A. Avinó et al., Protocols in Nucleic Acid Chemistry, 2020, 77: e78, doi: 10.1002/cpnc.78 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | N. Liu, Albert-Ludwigs-Universität Freiburg | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ![]() |